List view / Grid view

Dr Jack Hoppin (Ratio Therapeutics)

 

article

Targeting tumours with novel radiopharmaceuticals

In this exclusive Q&A, Dr Jack Hoppin, CEO, and Dr…

19 October 2023 | By , ,

In this exclusive Q&A, Dr Jack Hoppin, CEO, and Dr John Babich, Chief Scientific Officer of Ratio Therapeutics share their perspective on the evolving radiopharmaceutical landscape and why radiopharmaceutical therapeutics have significant potential in oncology.